Skip to main content
TSHA logo

TSHA · Taysha Gene Therapies, Inc. · Documents

Track TSHA — free
$3.99 -0.01 (-0.25%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$1.30B
Shares
326.05M
Volume · Nov 18 3.55M Avg daily vol (3M) 3.62M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $9.77M up 17.3% 10-K filed Mar 19, 2026 Quarterly report New FY2026 Q3 Revenue $0 10-Q filed Nov 12, 2026 Latest results New TSHA-102 PPQ campaign completed 8-K filed Nov 12, 2026 Earnings call New Q3 2026 earnings call Held Nov 12, 2026
2026
Nov 12
Earnings call
All 33 patients cleared acute safety monitoring

Tayshia said all 33 patients cleared acute safety monitoring, with no severe treatment-related serious adverse events or dose-limiting toxicities as of the November 2026 cutoff. Six-month interim data and FDA pathway feedback are expected in the first half of 2027.

3 source passages
Following the completion of dosing in both the Reveal Pivotal and Aspire trials, we are pleased to announce that all 33 patients dosed with Tayshia 102, 29 in the Reveal Phase 1-2 and Pivotal trials, and 4 in the Aspire trial have cleared the acute post-dosing safety monitoring period associated with AAV gene therapies. Notably, across the broader... Tayshia 102 clinical program, which began over three years ago, 33 patients spanning a broad range of ages, genotypes, and disease severities have been treated, with no severe treatment-related serious adverse events or dose-limiting toxicities reported as of the November 2026 data cutoff, supporting a favorable and consistent safety profile for trial participants across the program. We continue to expect to report full top-line data from the interim analysis and potential feedback from the FDA on next steps in the BLA submission pathway in the first half of 2027. Open the document at this passage
Nov 12
Current report 8-K
TSHA-102 PPQ campaign completed

Taysha Gene Therapies completed TSHA-102’s BLA-enabling PPQ campaign, meeting predefined specifications and comparability criteria; topline data from the REVEAL pivotal 6-month interim analysis and FDA feedback on the BLA submission pathway are expected in the first half of 2027.

Financial results
4 source passages
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. Completed BLA-Enabling Process Performance Qualification (PPQ) Campaign for TSHA-102. All process parameters and analytical results met predefined product specifications as well as comparability criteria for commercial product and clinical material. Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027 Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
TSHA-102 yielded milestone gains in all 12 patients

Taysha Gene Therapies said all 12 REVEAL Part A patients gained or regained at least one developmental milestone after TSHA-102. The 17-patient REVEAL pivotal trial has completed dosing, with topline data expected in the first half of 2027.

Revenue $0 Net loss $39.13M Diluted EPS -$0.10
Read from the MD&A section
3 source passages
As of the May 2026 data cutoff, 100% of the 12 patients in REVEAL Part A gained or regained ≥ one developmental milestone across the core functional domains of fine motor, gross motor and communication post-treatment with TSHA-102. We have completed dosing of the 17 patients aged 6 to <22 years in the overenrolled REVEAL pivotal trial, and enrollment for this trial is complete with a well-balanced age distribution across all pediatric, adolescent and adult patients dosed. We plan to discuss data from the 6-month interim analysis and next steps toward the BLA submission pathway with the FDA, with topline data and regulatory feedback anticipated in the first half of 2027. Open the document at this passage
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $0 Net loss $46.64M Diluted EPS -$0.13
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $0 Net loss $42.41M Diluted EPS -$0.12
Apr 22
Proxy statement DEF 14A Meeting Jun 1, 2026
Proxy statement AI summary on its way
Mar 19
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $9.77M ▲ 17.3% Net loss $109M Diluted EPS -$0.34
2025
Feb 26
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $8.33M ▼ 46.1% Net loss $89.3M Diluted EPS -$0.36
2024
Showing 1–50 of 171 documents
Key facts CIK 1806310 CUSIP 877619106 13F (30d) 217 filings 199 filers Visit website Investor relations